{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-010981","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.951501+00:00","generated_at":"2026-05-24T11:07:22.497493+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Abeona Therapeutics reports FY2024 net loss $63.7M, cash $98.1M, pz-cel PDUFA April 29","bullets":["Net loss of $63.7M ($1.55 per share) for FY2024 vs $54.2M ($2.53 per share) in FY2023.","Cash and investments total $98.1M as of Dec 31, 2024, up from $52.6M; runway into 2026.","FDA PDUFA target action date for pz-cel BLA is April 29, 2025; draft label received March 14.","If approved, first patient treatment with pz-cel expected in Q3 2025; launch prep with five QTCs underway.","Two additional patents for pz-cel extend protection to June 2037 and July 2040."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-010981","json":"https://secwatch.observer/filing/0001493152-25-010981.json","markdown":"https://secwatch.observer/filing/0001493152-25-010981.md","text":"https://secwatch.observer/filing/0001493152-25-010981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315225010981/0001493152-25-010981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315225010981/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T11:07:22.497493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}